Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318566 | 0.94 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL11661986 | 0.82 | — | — | |
| SCHEMBL2236262 | 0.81 | TSHR (0.34) | TSHRCETPCNR1CNR2 | |
| SCHEMBL9646862 | 0.79 | TSHR (0.38) | TSHRCETPCNR1CNR2 | |
| SCHEMBL11503129 | 0.79 | TSHR (0.38) | TSHRCETPCNR1CNR2 | |
| SCHEMBL22641147 | 0.79 | CPT1A (0.33) | TSHR | |
| SCHEMBL28756563 | 0.78 | TSHR (0.36) | TSHRCETP | |
| SCHEMBL892108 | 0.78 | TSHR (0.30) | TSHRALDH1A1CETP | |
| SCHEMBL15184839 | 0.78 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL27486763 | 0.77 | TSHR (0.38) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528907-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | Allergan, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | TUBB6, ANXA5, TUBB1 | TSHR 4009/4885ALDH1A1 898/4885CETP 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.